DRL launches nitroglycerin sublingual tablets in US

Image
Press Trust of India Hyderabad
Last Updated : Aug 29 2016 | 3:07 PM IST
Dr Reddy's Laboratories today said it has launched nitroglycerin sublingual tablets, a therapeutic equivalent generic version of Nitrostat (Nitroglycerin) sublingual tablets in the US.
The drug which is used in preventing or relieving a sudden attack of angina (chest pain) caused by heart disease was approved by the United States Food and Drug Administration (USFDA).
According to a statement issued by the drug maker, Nitrostat (Nitroglycerin) sublingual tablet brand had the US sales of about USD 108 million for the most recent 12 months ending in March 2016 (according to IMS Health data).
Dr Reddy's Nitroglycerin sublingual tablets USP, 0.4 mg is available in bottle count size of 100 and a bundle of 4 bottles of count size 25, Nitroglycerin sublingual tablets USP, 0.3 mg is available in bottle count size of 100 and the Nitroglycerin sublingual tablets USP, 0.6 mg is available in bottle count size of 100, it added.
DRL shares are trading at Rs 3,049.90 on BSE in afternoon session.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Aug 29 2016 | 3:07 PM IST

Next Story